Ivosidenib, an IDH1 inhibitor, in a patient with recurrent, IDH1-mutant glioblastoma: a case report from a Phase I study

Glioblastoma is the most common and aggressive primary brain tumor. Despite standard multimodality therapy, median overall survival remains poor with a 5-year survival rate of approximately 5% in most studies (range 4.7–13.0%). Strong interest in targeting IDH mutations has led to a variety of studi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tejera, Dalissa, Kushnirsky, Marina, Gultekin, Sakir H, Lu, Min, Steelman, Lori, de la Fuente, Macarena I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546125/
https://www.ncbi.nlm.nih.gov/pubmed/32716208
http://dx.doi.org/10.2217/cns-2020-0014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546125/
https://www.ncbi.nlm.nih.gov/pubmed/32716208
http://dx.doi.org/10.2217/cns-2020-0014

Ejemplares similares